BioVaxys Technology Corp.
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.
BioVaxys Technology Corp. (BIOV)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2024-0512 - Suspension - BioVaxys Technology Corp. (BIOV)
Le 16 mai/May 2024
Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the Ontario Securities Commission.
For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca
CSE Filings
